- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01236989
Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC (ARversusNAR)
November 8, 2010 updated by: University of Milan
Anatomical Liver Resection by Means of Ultrasound-guided Vessel Compression Versus Non-anatomical Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial
Prognostic impact of AR vs NAR
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
Whether anatomical is better than non anatomical resection for HCC is still debated.
This prospective randomized study aimed to address which approach is better in terms of patients prognosis.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Milan
-
Rozzano, Milan, Italy, 20089
- IRCCS Istituto Clinico Humanitas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patient affected by single HCC
- patients in whom liver resection is indicated
- HCC without vascular invasion and/or thrombosis
Exclusion Criteria:
- multinodular HCC
- metastatic disease
- spontaneous tumor rupture
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Anatomical resection
|
anatomical liver resection by means of IOUS-finger compression
|
|
Active Comparator: Non-anatomical resection
|
non-anatomical liver resection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the prognostic impact of anatomical resection by means of intraoperative ultrasound (IOUS) guided vessel compression versus nonanatomical resection in terms of disease free and overall survival
Time Frame: 5-years
|
5-years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the impact of anatomical resection versus non-anatomical resection in terms of postoperative mortality and morbility
Time Frame: 30 and 90 days
|
30 and 90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Guido Torzilli, MD, PhD, IRCCS Istituto Clinico Humanitas, Milan, Italy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg. 2005 Aug;242(2):252-9. doi: 10.1097/01.sla.0000171307.37401.db.
- Torzilli G, Procopio F, Cimino M, Del Fabbro D, Palmisano A, Donadon M, Montorsi M. Anatomical segmental and subsegmental resection of the liver for hepatocellular carcinoma: a new approach by means of ultrasound-guided vessel compression. Ann Surg. 2010 Feb;251(2):229-35. doi: 10.1097/SLA.0b013e3181b7fdcd.
- Torzilli G, Makuuchi M. Ultrasound-guided finger compression in liver subsegmentectomy for hepatocellular carcinoma. Surg Endosc. 2004 Jan;18(1):136-9. doi: 10.1007/s00464-003-9024-x. Epub 2003 Nov 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Anticipated)
December 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
October 29, 2010
First Submitted That Met QC Criteria
November 8, 2010
First Posted (Estimate)
November 9, 2010
Study Record Updates
Last Update Posted (Estimate)
November 9, 2010
Last Update Submitted That Met QC Criteria
November 8, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AR vs NAR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overall Survival
-
Peking University First HospitalCompletedOverall SurvivalChina
-
City of Hope Medical CenterNot yet recruitingOverall Survival (All-cause Mortality)United States
-
Guangdong Association of Clinical TrialsUnknown
-
Peking University First HospitalPeking University Third Hospital; Beijing HospitalActive, not recruitingSurgery | Elderly | Dexmedetomidine | Intensive Care Unit | Overall SurvivalChina
-
Shanghai Minimally Invasive Surgery CenterUnknownPostoperative Complications | Overall SurvivalChina
-
Hospital Universitario Virgen de la ArrixacaCompletedRecurrence | Overall Survival | Disease-free SurvivalSpain
-
Chinese PLA General HospitalRecruitingOverall Survival | Disease-free SurvivalChina
-
Qingdao Central HospitalCompletedOverall SurvivalChina
-
Peking Union Medical College HospitalOrigiMedRecruitingQuality of Life | Objective Response Rate | Overall Survival | Progression-free Survival | Disease Control Rate | Duration of Response | Five-year Survival RateChina
-
Shanghai CP Guojian Pharmaceutical Co., Ltd.CompletedAdverse Events | Progress-free Survival | Overall Response Rate
Clinical Trials on anatomical liver resection
-
Huazhong University of Science and TechnologyNot yet recruitingHepatocellular Carcinoma by BCLC StageChina
-
Sohag UniversityEnrolling by invitation
-
Fudan UniversityNot yet recruitingLiver Metastases | Colorectal CarcinomaChina
-
West China HospitalRecruiting
-
West China HospitalNanjing Chia-Tai Tianqing Pharmaceutical CompanyRecruitingRandomized Controlled Trial | Malignant Tumor of LiverChina
-
Centre Hospitalier Universitaire, AmiensCompletedLung Cancer | Surgery | Lobectomy | Video-assisted Thoracoscopic Surgery | SurvivalFrance
-
Fundación de Investigación Biomédica - Hospital...Marcello Di MartinoCompletedMetastatic Colorectal Cancer | Metastatic Liver CancerSpain, United Kingdom, France
-
Fudan UniversityCompletedThe Characteristics of CRLM Patients Who Would Benefit More From Anatomical Resection
-
University of MilanUnknownHepatocellular Carcinoma | Colorectal Liver Metastases | Liver MalignanciesItaly
-
hui houNot yet recruitingLaparoscopic Liver Resection | Open Liver ResectionChina